1. restriction of the analysis to the number of patients diagnosed with DVT, which is sometimes not equal to the number of patients initially randomised to the two treatments; 2. investigation of the effect of different diagnostic tests for the assessment of DVT on the estimation of a treatment effect; and 3. a safety analysis imputing other bleeding complications when wound haematoma was not reported.
Results of the review
Thirty-six double-blind studies (16,583 patients) were included.
The combined evaluation of studies in general and orthopaedic surgery showed a non significant reduction in the rate of DVT, with an OR of 0.92 (95% CI: 0.80, 1.05, p=0.19). In general surgery there was no increased efficacy in favour of high-dose LMWH (OR 0.88, 95 CI: 0.60, 1.30, P=0.53) , but there was a higher incidence of bleeding complications (OR 1.47, 95% CI: 1.07, 2.01, p=0.02). Low-dose LMWH was equally efficacious (OR 1.03, 95% CI: 0.85, 1.26, P=0.76), but safer than UFH (OR 0.68, 95% CI: 0.56, 0.82, P<0.01). In the safety analysis of high-and low-dose LMWH versus UFH , the study results were affected by heterogeneity. In orthopaedic surgery there was a trend towards an increased efficacy for LMWH (OR 0.83, 95% CI: 0.68, 1.02, P=0.07) with equivalent safety (OR 0.96, 95% CI: 0.68, 1.36, P=0.83). The Breslow-Day tests and sensitivity analyses (including analysis using the random-effects approach and examination of differences in loss of patients, variations in diagnostic methods and safety results) showed that the analysis of efficacy was affected by heterogeneity, thus limiting the generalisability of the results.
Authors' conclusions
In general surgical patients, low-dose LMWH and UFH were equally efficacious while low-dose LMWH provided increased safety over UFH. High-dose LMWH in general surgery did not increase the efficacy of treatment, although safety was strongly decreased. In orthopaedic surgery, LMWH provides an increase in efficacy over UFH, while preserving an equal safety profile. Heterogeneity affects these analyses and the generalisation of the results to other patients. New clinical trials should not be initiated, but published data should be reanalysed at the individual patient level to identify the subgroups of patients and decrease heterogeneity.
CRD commentary
The review appears to adhere to most of the key criteria of a systematic review, with clearly-outlined objectives, review criteria, methods of pooling and assessment of heterogeneity, along with well-presented study details. The only elements of the review that lack discussion are the criteria for assessing validity, and the methods used for applying the relevance and validity criteria.
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